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Introduction
Patients with heart failure with reduced ejection fraction
(HFrEF) and any degree of secondary mitral regurgitation
(MR) (SMR) have greater symptoms, higher hospitalization
rates, and shorter longevity than those without.1,2 However,
as a group, they often have more impaired left ventricular
(LV) function, are older, and have more co‐morbidities.3
Whilst medical and device therapies targeting the underlying
pathophysiology of HFrEF reduce SMR and improve
prognosis,4 whether treatments targeting SMR alter the
course of the underlying disease is unclear and has been
discussed for several decades.5 Furthermore, despite signifi-
cant progress including one positive randomized controlled
trial of edge‐to‐edge repair,4 there are still challenges ahead
that require the science to progress before the case is closed.
Are we accurately assessing secondary
mitral regurgitation?
In this issue of the Journal, Ströbe and colleagues contribute
important data describing the acute impact of the Carillon
device, a fully transvenous annular approach, adding to the
observations of longer‐term reductions in SMR and LV
remodelling seen in the randomized, sham‐controlled Carillon
Mitral Contour System for Reducing Functional Mitral
Regurgitation (REDUCE‐FMR) trial.6 Secondly, and perhaps
more importantly, they elegantly outline a strategy for the re-
producible echocardiographic assessment of SMR using mor-
phological and quantitative variables in the setting of HFrEF.7
The accurate assessment of the degree of MR seems a basic
concept; however, accurate quantification, particularly in
the setting of HFrEF, remains one of the greatest challenges
in echocardiography. An integrated approach consisting of
semi‐quantitative and quantitative parameters is
recommended8–10 but has limited reproducibility owing to
regional wall motion abnormalities, dyssynchrony, and LV re-
modelling, which introduce the potential for greater errors.11
The preferred quantitative measurement for both clinical
and research applications uses the proximal isovelocity surface
area (PISA). This has significant limitations including the fact
that the effective regurgitant orifice area, assumed to be
hemispheric, is actually elliptical, themeasurement of the PISA
radius is difficult, and any errors are squared in the calculation.
PISA can therefore lead to implausible results11 and unreliable
differentiation between even severe and non‐severe SMR.12
How can these challenges be
overcome?
Improvements in imaging techniques incorporating
three‐dimensional imaging with less reliance on geometric
assumptions have paralleled the advent of percutaneous
intervention for MR.13 There has also been an increasing
appreciation that accurate volumetric imaging, specifically
that of the LV, could describe MR in terms of regurgitant
volume (RVol) and regurgitant fraction (RF) as a product of
the systolic volume of the LV (SVLV) and the forward stroke
volume (SV forward) across the aortic valve:
SVLV ¼ end  diastolic LV volumeð Þ
 end  systolic LV volumeð Þ
RVol ¼ SVLV–SVforward
RF ¼ Rvol=SVLV
Quantitative volumetric methods are seldom used in clini-
cal practice and are not actively encouraged by guidelines10;
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however, Stöbe and colleagues have demonstrated that they
can be applied. More routine use of three‐dimensional echo-
cardiography would allow more widespread implementation
of this technique, which could be further complemented by
multi‐modality assessment.
Does more accurate assessment of
secondary mitral regurgitation matter?
Whether one chooses to adopt such a comprehensive or a
more pragmatic approach in routine clinical practice depends
somewhat on the proposed treatment, its mode of action,
and safety profile. For example, in contrast to the Transcath-
eter Mitral‐Valve Repair in Patients with Heart Failure
(COAPT) trial,4 local valve‐teams decided upon eligibility for
the annular treatment in REDUCE‐FMR.6 The inclusion of
patients with less severe SMR as assessed by subsequent
core‐laboratory analyses reduced the mean improvement in
SMR achieved (improving mild SMR is difficult). However, this
approach had the effect of delivering information on a wider
range of patients including a group in whom, based upon the
observation that any degree of SMR is associated with a
worse outcome, one could envisage a future strategy of
low‐risk prevention. Secondly, REDUCE‐FMR also provides
reassurance to future payers, clinicians, and patients of
potential outcomes in patients recruited in real‐world
situations outside of core‐laboratory control. Given the
adverse impact of any SMR on outcomes, it is plausible that
a safe, simple, and preferably inexpensive procedure might
be applied at a much earlier stage obviating the need for
accurate assessment. But we are not at that stage yet.
Proportionate and disproportionate
secondary mitral regurgitation
Although to many, the case for mitral valve‐targeted treat-
ments in HFrEF is closed, this strategy is based on a single
randomized trial of a single technique in a highly controlled
setting.4 The divergent results of the Percutaneous Repair
of Medical Treatment for Secondary Mitral Regurgitation
(MITRA‐FR) study14 has led to a plausible concept of propor-
tionate SMR (appropriate for the degree of LV remodelling)
and disproportionate SMR (greater than would be expected
for the degree of LV remodelling),15 where those with dispro-
portionate SMR might benefit more from valve‐targeted in-
tervention. However, recent data from the COAPT study do
not support a heterogeneity of effects on clinical outcomes
in patients by baseline LV volume.16 Moreover, one cannot
assume that any such concept holds for newer or less studied
devices with different modes of action. For example, in
COAPT, although those allocated to intervention had lesser
progression of remodelling, neither group experienced
reverse remodelling,16 a consistent observation in patients
treated with the Carillon device.17 Finally, whether this model
reflects differing pathophysiology or merely the duration of
the HFrEF syndrome is unknown and will require longitudinal
follow‐up of those with untreated disproportionate SMR to
determine if in time they become patients with proportionate
SMR. Hence, caution should be exercised when (de)selecting
patients who have severe proportionate SMR despite optimal
medical therapy until we have more information from studies
that support this paradigm. Both groups, including those with
disproportionate SMR and HFrEF, should continue to receive
optimal medical therapy targeting the renin–angiotensin–
aldosterone system and beta‐adrenoceptor antagonists in
addition to being considered for device therapy.13
Pathophysiological mechanisms and
co‐morbidities guiding therapeutic
approach in secondary mitral
regurgitation
Although much attention is given to the assessment of the
degree of SMR, the growing number of transcatheter devices
offers the opportunity but also the challenge of selecting the
most appropriate device, or combination of devices to treat
patients with SMR based upon the pathophysiology. The
mechanisms underlying SMR are heterogeneous with LV
remodelling, regional wall motion abnormalities due to
ischaemia, infarction, and electromechanical dyssynchrony
being accepted as underlying contributors, whilst annular
deformation, annular dilatation, mitral valve leaflet area,
degree of leaflet tethering, and left atrial function differ
significantly depending on underlying aetiology.
The status of the patient should also contribute to the
choice of device through a coordinated multi‐disciplinary
team approach. For example, a fully transvenous annular
treatment might be more effective in patients with more
adverse remodelling and could be considered in patients with
co‐morbidities or with milder SMR in whom a shorter,
low‐risk procedure might be preferable. On the other hand,
a combined approach, although providing the greatest
reduction in SMR, needs to balance risk, cost, and clinical
outcomes.
Atrial functional MR (AFMR) might be an additional ideal
target for the Carillon device. The prevalence of AFMR is
reported to be 3–15% of patients with atrial fibrillation18 and
15.9% in patients hospitalized with heart failure who have
preserved ejection fraction.19 In contrast to SMR caused by
LV dysfunction and dilatation, in AFMR, LV dimensions and
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systolic function are normal, leaving mitral annulus dilatation
as the key driver of mitral leaflet malcoaptation.
Measuring ‘response’ to treatments for
secondary mitral regurgitation
Measuring the benefit of therapies in HFrEF is difficult owing
to the variable symptom burden and inexorable deterioration
expected even in patients receiving optimal therapies.
Because of this, patient‐orientated outcomes such as exercise
capacity, symptoms, and survival cannot be reliably assessed
from longitudinal data.20 For individual patients, staying the
same and deteriorating more slowly are meaningful
outcomes that are only possible to determine by comparisons
with the unimplanted. The lessons learned from cardiac
resynchronization therapy (CRT) are relevant.21 Observational
studies could have the unintentional consequence of (de)
selection of patients in clinical practice who have little chance
of ‘response’ thereby risking undertreating a population,
within which the oldest, the frailest, and those with
co‐morbidities potentially have the greatest proportional gain
from intervention. Moreover, the relationship between the
severity of SMR and outcomes is not linear; and as demon-
strated by the conflicting results of COAPT, MITRA‐FR, and
surgical data, reductions in SMR do not automatically
improve outcomes4,14,22 and cannot be assumed (yet) to be
a reliable surrogate of patient‐orientated outcomes.
Future outcome trials
Device therapies for SMR will only be widely adopted and
incorporated into guidelines if supported by randomized con-
trolled trials, preferably with blinding where possible to avoid
differential follow‐up and nocebo effects. These trials need to
be powered to avoid the pitfalls of strict entry criteria that
limit generalizability and subsequent subgroup analyses. If
longitudinal data must be used whilst we wait for the
outcomes of further trials, the Packer clinical composite score
is an adequate compromise that includes failure to deterio-
rate as a positive outcome, which in CRT is associated with
a similar benefit on long‐term mortality as ‘response’.23
Conclusions
We have made great progress, and new classifications of SMR
and its pathophysiology have moved the field forward
greatly, but we must be willing to ‘validate, refute or modify’
our strategy15 for the benefit of current and future patients.
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